Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT

Background Chronic kidney disease affects around 10% of the global population and is associated with significant risk of progression to end-stage renal disease and vascular events. Aldosterone receptor antagonists such as spironolactone have shown prognostic benefits in patients with heart failure,...

全面介紹

書目詳細資料

Principais autores:	F D Richard Hobbs, Richard McManus, Clare Taylor, Nicholas Jones, Joy Rahman, Jane Wolstenholme, Louise Jones, Jennifer Hirst, Sam Mort, Ly-Mee Yu
格式:	Artigo
語言:	Inglês
出版:	NIHR Journals Library 2025-03-01
叢編:	Health Technology Assessment
主題:	chronic kidney disease ckd moderate ckd, ckd treatment prevention spironolactone cardiovascular risk clinical trial
在線閱讀:	https://doi.org/10.3310/PYFT6977
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!